Day One Biopharmaceuticals Receives HSR Clearance for Servier Tender Offer
DAWN has more than doubled off its 52-week low of $5.635.
Summary
Day One Biopharmaceuticals announced that a key regulatory condition for its acquisition by Servier has been satisfied, moving the tender offer closer to completion.
Key Events · M&A and Partnerships · DAWN
-
HSR Act Clearance Granted
The Federal Trade Commission (FTC) granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, effective April 7, 2026.
-
Tender Offer Condition Satisfied
This regulatory approval satisfies a key condition for Servier's tender offer to acquire all outstanding shares of Day One Biopharmaceuticals for $21.50 per share, as initially announced on March 26, 2026.
Analysis · DAWN · Life Sciences
This amendment confirms that the Federal Trade Commission (FTC) has granted early termination of the waiting period under the HSR Act, a critical regulatory approval for Servier's tender offer to acquire Day One Biopharmaceuticals. The satisfaction of this condition removes a significant hurdle, increasing the certainty and accelerating the timeline for the acquisition to close. This is a positive development for shareholders awaiting the completion of the $21.50 per share all-cash offer.
At the time of this filing, DAWN was trading at $21.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.